Assessment of Safety and Prophylactic Efficacy of the EpiVacCorona Peptide Vaccine for COVID-19 Prevention (Phase III).

The State Research Center of Virology and Biotechnology "VECTOR" of the Federal Service for the Oversight of Consumer Protection and Welfare (Rospotrebnadzor) has developed the peptide-based EpiVacCorona vaccine, which is the first synthetic peptide-based antiviral vaccine for mass immunization in international vaccinology. An early clinical trial (Phase I-II) demonstrated that the EpiVacCorona vaccine is a safe product. The "Multicenter double-blind, placebo-controlled, comparative, randomized trial to assess the tolerability, safety, immunogenicity and prophylactic efficacy of the EpiVacCorona COVID-19 vaccine based on peptide antigens in 3000 volunteers aged 18 years and older" was performed regarding vaccine safety.

Banks of cell cultures for biotechnology.

Seeding and working cell banks were created and stored in cell culture collection. The banks were certified in accordance with international and national requirements. Cultures of 293, MT-4, L-68, FECH-16-1, FECH-16-2, 4647, MDCK, CHO TK(-), and CHO pE cells were recommended by Medical Immunobiological Preparation Committee for the use in the production of medical immunobiological preparations.